Dr. Frank Weinberg
Claim this profileUniversity of Illinois
Studies Solid Tumors
Studies Lung Cancer
11 reported clinical trials
21 drugs studied
Area of expertise
1Solid Tumors
Stage III
Stage IV
Stage II
2Lung Cancer
Stage III
Stage IV
Stage II
Affiliated Hospitals
Clinical Trials Frank Weinberg is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Temozolomide + Atezolizumab
for Small Cell Lung Cancer
This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving temozolomide and atezolizumab as second or third line treatment may help prolong survival in patients with small cell lung cancer.
Recruiting1 award Phase 215 criteria
More about Frank Weinberg
Clinical Trial Related4 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Frank Weinberg has experience with
- Pembrolizumab
- Carboplatin
- Pemetrexed
- Paclitaxel
- Nab-paclitaxel
- GT103
Breakdown of trials Frank Weinberg has run
Solid Tumors
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Frank Weinberg specialize in?
Frank Weinberg focuses on Solid Tumors and Lung Cancer. In particular, much of their work with Solid Tumors has involved Stage III patients, or patients who are Stage IV.
Is Frank Weinberg currently recruiting for clinical trials?
Yes, Frank Weinberg is currently recruiting for 8 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Frank Weinberg has studied deeply?
Yes, Frank Weinberg has studied treatments such as Pembrolizumab, Carboplatin, Pemetrexed.
What is the best way to schedule an appointment with Frank Weinberg?
Apply for one of the trials that Frank Weinberg is conducting.
What is the office address of Frank Weinberg?
The office of Frank Weinberg is located at: University of Illinois, Chicago, Illinois 60612 United States. This is the address for their practice at the University of Illinois.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.